Skip to main content
. 2017 Jun 27;8(33):55116–55134. doi: 10.18632/oncotarget.18664

Figure 5. Effects of Aurora kinase inhibitor II treatment of PCa cells +/- RALA and miR-331-3p.

Figure 5

(A) Varying concentrations of AKi-II were used to establish an EC50 of the inhibitor in LNCaP and 22Rv1 PCa cells. (B) LNCaP PCa cells were treated with 10 μM AKi-II over 5 days and proliferation was measured via cell titre. (C) The effect pretreatment of LNCaP PCa cells with miR-331-3p has on the EC50 concentration of Aki-II. (D) Effects on colony formation of LNCaP PCa cells between miR-NC/miR-331-3p treated cells vs miR-NC/miR-331-3p and AKi-II treated cells. (E) Effects of si-RALA treatment on colony formation between si-RALA treated vs si-RALA and AKi-II treated 22Rv1 PCa cells. *p<0.05; CI=0.95; n=3, Error bars = SD.